Skip to main content

Table 1 Efficacy and adherence rates across PrEP trials

From: Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?

Study [reference]: countries

Population

n

Efficacy

Lower bound of 95% CI

Adherencea

Partners PrEP [8]: Kenya, Uganda

Heterosexual couples

4758

67% TDF; 75% TDF/FTC

44% TDF; 55% TDF/FTC

82%

TDF2 Study [9]: Botswana

Young men and women

1219

62% TDF/FTC

21.5%

80%

Bangkok TDF [12]: Thailand

IVDU

2413

49% TDF

9.6%

67%

iPrEx [7]: S. America, SA, Thailand, USA

MSM

2499

44% TDF/FTC

15%

51%

FEM-PrEP [10]: Kenya, SA, Tanzania

Young women

2120

6% TDF/FTC

−52%

37%

VOICE [11]: South Africa, Uganda, Zimbabwe

Young women

5029

−49% TDF; - 4% TDF/FTC

−130% TDF; −50% TDF/FTC

30%

  1. Abbreviations: FTC, emtricitabine; IVDU, intravenous drug users; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; SA, South Africa; TDF, tenofovir disoproxil fumarate.
  2. aAdherence was assessed by the proportion of participants with drugs detectable in plasma and who remained free of infection in the active PrEP arms.